SOURCE: Peak Pharmaceuticals, Inc.

Peak Pharmaceuticals, Inc.

June 09, 2015 09:00 ET

Peak Pharma Readies New Product Lineup for Canna-Pet®

Company Continues to Expand Its Product Portfolio and Revenues

BOULDER, CO--(Marketwired - Jun 9, 2015) - Peak Pharmaceuticals, Inc. (OTCQB: PKPH) ("Peak Pharma" or the "Company"), a leading innovator of non-prescription hemp based cannabinoid products, and exclusive license holder for Canna-Pet, today announced the development and plans for release and marketing of Canna-Pet® Advanced120, a new product targeting small to mid-sized animals.

Formulated with Canna-Pet® Advanced, the new 120mg product targets delivery of the entire cannabinoid profile of hemp, including CBD and terpenes. The Canna-Pet® Advanced120 is designed for small to mid-sized pets, and would be an appropriate supplement for all cat and dog breeds.

The Canna-Pet® Advanced supplement was prepared based on in-house data and customer feedback, including responses from a recent customer survey. The formulation will first appear in the Canna-Pet® Advanced120 product, and later this year the company plans to include it in a new line of biscuit treats.

Canna-Pet was one of the first companies to discover that some pets thrive with hemp supplementation as part of their diet. The Canna-Pet® Advanced120 supplements are being produced in a cGMP manufacturing facility to ensure the highest level of product quality and consistency, a cornerstone of Peak Pharma's product philosophy. Similar to the company's current products, the Advanced formula includes proprietary ratios of hemp-derived cannabinoids and terpenes, and the manufacturing process is designed to produce a supplement that mimics as closely as possible the phytochemical profile of the hemp plant. Hemp is a member of the cannabis family and produces CBD among many cannabinoids, but contains only trace amounts of the psychoactive compound THC, which can be toxic to animals. The fact that the Canna-Pet® product lineup is based on hemp and virtually devoid of THC differentiates it from those products made from "marijuana" or "pot."

"We are delighted to announce this second generation product within the first year of our Canna-Pet® license agreement," says Company CEO Dr. Soren Mogelsvang. "Canna-Pet® has enjoyed steady month over month sales growth and we have recently identified several areas where we believe there is room to improve the Company's product lineup. The Canna-Pet® Advanced120, for example, will be our first product to be released in redesigned packaging, and it will feature industry standard bottles with updated messaging to clearly distinguish our merchandise. This new initiative illustrates our continuous commitment to deliver quality products to pet owners, and reemphasizes our aim to maintain a leading role in the rapidly growing hemp industry."

About Peak Pharmaceuticals, Inc. (OTCQB: PKPH)
Peak Pharmaceuticals, Inc. specializes in the development, manufacturing, sales and marketing of pharmaceutical-grade, hemp-based supplement products for the human and animal health markets. The company aims to become a global leader in the hemp supplement industry. For more information visit and follow us on Facebook, Twitter and LinkedIn.

About Canna-Pet® Products for Pet Health
Canna-Pet® offers non-prescription CBD products for domesticated animals such as cats and dogs. Canna-Pet® is the culmination of years of research and development to provide the benefits of hemp-based CBD and cannabinoids without the "high" typically associated with psychoactive cannabis products. The company uses non-GMO hemp as starting material and all products are proudly manufactured in the USA. In addition to CBD, Canna-Pet products differ from its competitors through the use of proprietary ratios of hemp derived cannabinoids and terpenes. Canna-Pet® is a trademarked, leading producer of safe, hemp-based, cannabidiol (CBD) containing products, which are available under an exclusive commercial license agreement with Peak Pharmaceuticals, Inc. (OTCQB: PKPH). Order online at: or under "Pet Supplies" on Amazon, and join us on Facebook and Twitter.

Additional details of Peak Pharmaceuticals business, finances, appointments, risks and agreements can be found as part of the Company's continuous public disclosure as a reporting issuer with the Securities and Exchange Commission ("SEC") available at For more information please visit

Safe Harbor Statement
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the availability of additional funding; the early-stage nature of the industry sector; regulatory changes affecting the sale, transport or consumption of Cannabidiol or hemp based products by humans or animals; commercial impacts to the Company's business, related agreements, product development, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in the Company's filings with the SEC, including, the Company's current reports on Form 8-K. The Company does not undertake to update these forward-looking statements. FDA Disclosure: The statements in this news release have not been evaluated by the U.S. Food and Drug Administration (USFDA). The products mentioned herein are not intended for human consumption, or to diagnose, treat, cure, or prevent any disease. Information contained or made available through the Canna-Pet® website or affiliate sites is not intended to constitute or substitute for legal or veterinary advice.

Contact Information